✦ LIBER ✦

5029 Motesanib (AMG 706) in combination with paclitaxel or docetaxel: phase 1b study in patients with locally recurrent, unresectable or metastatic breast cancer

✍ Scribed by P. Kaufman; R. de Boer; S. White; P. Mainwaring; B. Koczwara; L.M. Urquhart; Y. Ye; Y. Sun; H. Adewoye; D. Kotasek

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of locally recurrent, unresect

✍ R. de Boer; P. Kaufman; S. White; P. Mainwaring; B. Koczwara; Y. Ye; Y. Sun; M. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Phase 1b dose-finding study of motesanib

✍ Richard H. De Boer, Dusan Kotasek, Shane White, Bogda Koczwara, Paul Mainwaring, 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 342 KB

Phase I/II study of S-1 combined with pa

✍ Mochiki, E; Ohno, T; Kamiyama, Y; Aihara, R; Haga, N; Ojima, H; Nakamura, J; Ohs 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 106 KB

Phase II Study of Weekly Docetaxel Alone

✍ Joshua P. Raff; Lakshmi Rajdev; Umekalsoom Malik; Yelena Novik; Jane M. Manalo; 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 126 KB

First-line therapy with gemcitabine and

✍ Djelila Allouache; Sulochana R Gawande; Michele Tubiana-Hulin; Nicole Tubiana-Ma 📂 Article 📅 2005 🏛 BioMed Central 🌐 English ⚖ 275 KB

Motesanib, or open-label bevacizumab, in

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB